Genetics & R&D
Regeneron gene therapy approved by FDA
What’s happening
The U.S. Food and Drug Administration approved a gene therapy from Regeneron Pharmaceuticals for a rare genetic form of deafness.
What’s changing / Business impact
- First gene therapy for this condition enters the market
- Expands use of gene therapy beyond rare diseases into broader applications
- Introduces new commercialization models (free access for patients initially)
Why this matters
FDA approvals don’t just add drugs, they expand entire treatment categories.
This shows:
- Gene therapy is moving from niche → mainstream therapeutic approach.
- Innovation is shifting toward one-time, high-impact treatments.
- Approval signals where future investment will concentrate.